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SummaηSerum levels of apolipoproteins were determined in 386 outpatients 
without obvious metabolic disorder by turbidimetric immunoassay. By studies on linearity， 
repeatability， reproducibility and interference， this assay was confirmed to be applicable for 
routine laboratory tests. Clinical reference ranges in serum levels of apolipoprotein (apo) 
A-1， A-II， B， C聞 I，C-II， and E were 92. 56-173. 79， 2. 11-40. 34， 52. 53-110. 37， 1. 39-5. 44， 
4. 27-12. 94 and 2. 87-6. 38 mg/dl， respectively. Also， comparative studies on skewness and 
coefficient of variation in distribution of values were done with apo A-1 and high-density 
lipoprotein (HDL) cholesterol， and apo B and low-density lipoprotein (LDL) cholestero1. 
The findings suggested that levels of apolipoproteins such as A-1 and B are related to 
partic1e numbers of lipoproteins such as HDL and LDL， while cholesterol content in 
lipoproteins is affected by qualitative changes in partic1es as wel1. In coronary heart 
diseases， apo B and apo B/ A-1 ratios were significant1y elevated and are suggested to be 
sensitive indicators for these diseases. 
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アポA-1 240 mg! dl，アポA-II73.0mg!dl，アポ B
215 mg! dl，アポ C-I 9.0 mg! dl，アポ C-III50.0 mg!dl， 
アポE8.0 mg!dlまで良好な直線性が得られた (Fig.1). 
b)同時再現性
3種の血清についてそれぞれ 20回測定を行ない，変動































Fig. 1. Lineariti巴sin det巴rminationof apolipoprotein A同 1，A-II， B， C-II， C-III and E. 
(400) 中井
係数 (CV)を求めた.各 CVはアポ A-1 0.88-1.73 
%，アポA-II0.95-2.94%，アポ B1.25-2.80 %，ア
ポC-I 1.66-8.83 %，アポ C-1I1.86-9.06 %，アポ
E 1.20-11.09 %で、あっTこ. iEl L，アポ C-I， C -II， 






たところ，一部(アポ C-III，Eにおいて m巴an=3.090mg 





アポ C-IIIを除いてピリノレピン 40mg/ dl，ヘモグロピン
550 mg/dl，乳び 2.0%までほとんど影響はみられなかっ
た. アポ CIIIはピリノレビン 20mg/ dlで約 18%の正誤差，
































Table 1. Serum levels of apolipoprot巴inA-1 ， A-II， B， C-II， C-III， and E 
Age Sex Case No A-1 (mg/ dl) A目 I (mg/ dl) B (mg/dl) 
20-29 Male 29 124.4土25.55 32.6土5目17 76.2土25.76
Female 32 138.9士24.73* 30.4士6.00 84.7土20.23
30-39 Male 23 126.3土23.32 33.4士5.62 98.0士28.76
Female 23 139.2土27.65 32.5土7.06 84.l:t22.19 
40-49 Male 54 121.2:1=28.10 31.8士6.86 92.2土21.12
Female 82 135.6土23.52* 32.0土5.42 91.5土22.97
50-60 Male 70 128.5:1=27.26 32.7士8.15 104.0士29.57
Female 73 135.7土21.66 33.2土6.73 104.5土24.31
Age Sex C-I (mg/ dl) C-I (mg/ dl) E (昭/dl)
20-29 Male 3.09土1.358 8.73士5.150 4.36土1.411
Female 3.09士1.103 10目02土6.219 5.06:1=1. 715 
30-39 Male 4.28土1.722 12.24土7.449 5.30土1.916
F巴male 3.16:1=1.310本 9.57士5.871 4.69士1.193
40-49 Male 4.20士1.753 10.25土4.864 5.05土1.299
Female 3.54土1.484 * 9.89士4.392 5.50士1.568
50-60 乱i[ale 4.76土2.122 13.24:1=7.221 6.11:1=2.327 
Female 4.03士1.314 * 10.58土3.938ホ 5.69土1目396
Data are expressed as mean土SD.
車 p< 0.05 compared with male data of same age-group. 
p<0.05， p<O.Ol compared with the preceding decade's data with same sex 
(401) アポリポ蛋白の免疫比濁法による測定とその診断的意義について
Table 2. Clinical r巴ferencerange (CRR) and skewn巴sfor normal distri-
bution of apo!ipoprot巴inA悶 1，A四 I，B， C-II， C-Il， HDL-Ch and 
LDL-Ch levels in cases with serum levels of TCh三五220mg/ dl 
and TG=150 mg/dl (Case number=186) 
A -1 (mg/ dl) A -I (mg/ dl) B (mg/dl) 
52.53~110.37 
0.145 
2 .1 ~ 40 . 34
0.055 
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Fig. 2. Relationships b巴tw巴巴napolipoprotein A-1 and HDL-Ch， and apolipoprotein B and LDL-Ch 
(402) 中井 忍(他 8名〉
Table 3. Lipoprot巴inprofil，e in patients with fresh coronary h巴art
diseases (CHD) 
CHD (n=7) Control (n = 186) 
TCh (mg/dl) 
HDL.Ch (mg/ dl) 
LDL.Ch (mg/ dl) 









apo B Cmg/ dJ) 





B/ A-1 ratio 0.93士0.164ヰキ
Data are expressed as mean土SD.
* p < 0.05， * * p < 0.01 compared with control 
Values of TCh， HDL.Ch and LDL.Ch are shown in Tabl巴2，
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